Clinical response to bevacizumab in schwannomatosis

Neurology. 2014 Nov 18;83(21):1986-7. doi: 10.1212/WNL.0000000000000997. Epub 2014 Oct 22.

Authors

Jaishri Blakeley¹, Karisa C Schreck², D Gareth Evans¹, Bruce R Korf¹, David Zagzag¹, Matthias A Karajannis¹, Amanda L Bergner¹, Allan J Belzberg¹

Affiliations

¹ From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York.
² From The Johns Hopkins Hospital (J.O.B., K.C.S., A.L.B., A.J.B.), Baltimore, MD; St. Mary's Hospital (D.G.E.), Manchester, UK; University of Alabama at Birmingham (B.K.); and NYU Langone Medical Center (D.Z., M.A.K.), New York. [email protected].

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Bevacizumab
Humans
Male
Neurilemmoma / diagnosis*
Neurilemmoma / drug therapy*
Neurofibromatoses / diagnosis*
Neurofibromatoses / drug therapy*
Skin Neoplasms / diagnosis*
Skin Neoplasms / drug therapy*
Young Adult

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab

Supplementary concepts

Schwannomatosis

Grants and funding